Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 3,100 shares, a decrease of 91.8% from the August 15th total of 37,800 shares. Based on an average trading volume of 338,600 shares, the days-to-cover ratio is presently 0.0 days.

Provectus Biopharmaceuticals Trading Up 0.3 %

PVCT stock traded up $0.00 during trading on Thursday, hitting $0.11. 44,600 shares of the company traded hands, compared to its average volume of 254,305. The company has a 50-day moving average of $0.11 and a 200-day moving average of $0.15. Provectus Biopharmaceuticals has a 1 year low of $0.04 and a 1 year high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.